BMS-986202,1771691-34-9

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BMS-986202

CAS No. : 1771691-34-9

MCE 国际站：BMS-986202

产品活性：BMS-986202 是一种有效的，选择性的，具有口服活性的 Tyk2 抑制剂，可与 Tyk2 JH2 结合，IC₅₀ 为 0.19 nM，K_i 为 0.02 nM。BMS-986202 对包括 Jak 家族成员在内的其他激酶具有高度选择性。BMS-986202 还是 CYP2C19 的弱抑制剂，IC₅₀ 为 14 μM。BMS-986202 可用于 IL-23 驱动的棘皮症，抗 CD40 诱导的结肠炎和自发性狼疮的研究。BMS-986202 是一种从头设计的氘代物。

研究领域：Epigenetics  |  Protein Tyrosine Kinase/RTK  |  JAK/STAT Signaling  |  Stem Cell/Wnt  |  Metabolic Enzyme/Protease

作用靶点：JAK  |  Cytochrome P450

In Vitro: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
Potential advantages of deuterated compounds:
(1) Extend the half-life in vivo. Deuterated compounds may be able to prolong the pharmacokinetic characteristics of the compound, that is, prolong the half-life in vivo. This can improve compound safety, efficacy and tolerability, and increase ease of administration.
(2) Improve oral bioavailability. Deuterated compounds may reduce the degree of unwanted metabolism (first-pass metabolism) in the gut wall and liver, allowing a greater proportion of the unmetabolized drug to reach its target site of action. High bioavailability determines its activity at low doses and better tolerance.
(3) Improve metabolic characteristics. Deuterated compounds may reduce the formation of toxic or reactive metabolites and improve drug metabolism.
(4) Improve drug safety. Deuterated compounds may reduce or eliminate adverse side effects of pharmaceutical compounds and are safe.
(5) Preserve the therapeutic properties. Deuterated compounds are expected to retain similar biochemical potency and selectivity to hydrogen analogs in previous studies.

In Vivo: BMS-986202 (Compound 7; 3-30 mg/kg; p.o.; daily; for 9 days) treatment inhibits IL-23-driven acanthosis in mice.
BMS-986202 (Compound 7; 0.4-10 mg/kg; p.o.) treatment inhibits IL-12/IL-18-induced IFNγ production in mice. BMS-986202 dose-dependently inhibits IFNγ production by 46% and 80% at doses of 2 mg/kg and 10 mg/kg, respectively.
BMS-986202 (Compound 7; 7-10 mg/kg; p.o.) is stable in liver microsomes, with half lives of greater than 120 min in mouse, rat, monkey, and humans and 89 min in dog. The serum protein binding for BMS-986202 in these species ranges from 89.3% to 96.0%, leaving a good range of free fraction of drug available. BMS-986202 shows the oral bioavailability up to 62-100%.

相关产品：Ruxolitinib  |  Tofacitinib  |  Deucravacitinib  |  Baricitinib  |  AG490  |  Upadacitinib  |  Verapamil  |  Fedratinib  |  Apigenin  |  Fenofibrate  |  Chlorpromazine hydrochloride  |  Ketoconazole  |  1-Aminobenzotriazole  |  Letrozole  |  Abiraterone  |  Itraconazole  |  Pacritinib  |  Ritlecitinib  |  Momelotinib  |  WP1066  |  Cepharanthine  |  Filgotinib  |  Quinidine (15% dihydroquinidine)  |  Butyzamide  |  Diosmetin  |  Clarithromycin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds